Pharming Group (NASDAQ:PHAR) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Posted by Brian Himes on Jul 30th, 2026

Pharming Group (NASDAQ:PHAR – Get Free Report) issued its earnings results on Thursday. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.04), FiscalAI reports. Pharming Group had a net margin of 3.30% and a return on equity of 4.64%.

Here are the key takeaways from Pharming Group’s conference call:

2026 revenue guidance was reduced by $30 million to $375 million–$395 million, reflecting continued competitive pressure on RUCONEST and a 0%–5% expected revenue growth range.
RUCONEST revenue fell 10% year over year to $72.3 million, but management highlighted resilience in the active patient base, which remained at 93% of prior-year levels, and a recovery in new enrollments to 84 in Q2. The company expects RUCONEST revenue to stabilize and return to growth in the second half of 2026.
JOENJA revenue grew 40% to $17.9 million, with U.S. revenue up 31% and international revenue up 150%. Growth is expected to be supported by launches in Germany and Japan, further U.S. patient identification, and potential pediatric label expansion.
Two fully enrolled phase II studies evaluating leniolisib in broader primary immunodeficiencies and CVID are expected to produce results in Q4 2026. Positive data could expand JOENJA’s addressable population substantially—CVID is estimated to be up to 40 times larger than APDS—and support a potential blockbuster franchise.
Pharming reduced full-year operating expense guidance by $15 million to $315 million–$320 million while continuing more than $40 million of incremental R&D investment. Q2 operating profit remained positive, but operating cash flow was negative $9.7 million and cash and marketable securities declined to $159.5 million.

Pharming Group Stock Down 10.5%

Shares of Pharming Group stock traded down $1.26 during trading hours on Thursday, hitting $10.75. The company had a trading volume of 49,554 shares, compared to its average volume of 5,623. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.63 and a quick ratio of 2.06. The company’s 50-day moving average is $13.07 and its two-hundred day moving average is $15.23. The company has a market cap of $760.88 million, a P/E ratio of 67.19 and a beta of -0.04. Pharming Group has a twelve month low of $9.62 and a twelve month high of $21.34.

Institutional Investors Weigh In On Pharming Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. EverSource Wealth Advisors LLC acquired a new position in Pharming Group in the second quarter valued at $32,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Pharming Group during the fourth quarter worth about $224,000. Millennium Management LLC acquired a new stake in shares of Pharming Group during the fourth quarter worth about $360,000. Finally, NewEdge Advisors LLC lifted its holdings in shares of Pharming Group by 11,310.3% in the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company’s stock valued at $510,000 after purchasing an additional 28,615 shares during the last quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on PHAR shares. Oppenheimer reissued an “outperform” rating on shares of Pharming Group in a research report on Thursday. Canaccord Genuity Group started coverage on shares of Pharming Group in a research report on Friday, April 10th. They set a “buy” rating and a $37.00 price objective for the company. Zacks Research raised Pharming Group from a “strong sell” rating to a “hold” rating in a report on Friday, April 10th. Weiss Ratings cut Pharming Group from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen downgraded Pharming Group from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $38.33.

Read Our Latest Stock Report on PHAR

About Pharming Group

(Get Free Report)

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.